CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today a new framework for value-based agreements (VBAs) designed to ...
The primary hyperoxalurias are a group of autosomal recessive disorders involving the overproduction of oxalate. Although the initial recognition of the disease is attributed to Lepoutre, who reported ...
Credit: Getty Images. Rivfloza is a small interfering RNA therapeutic. The Food and Drug Administration (FDA) has approved Rivfloza™ (nedosiran) to lower urinary oxalate levels in children 9 years of ...
Primary hyperoxaluria type 1 (PH1) is one of a group of rare diseases that are genetic, or inherited from your parents. Primary hyperoxalurias affect your metabolism -- your body's process for turning ...
New York, USA, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Primary Hyperoxaluria Market to Exhibit Substantial Growth Rate by 2032, Assesses DelveInsight | Leading Companies - Alnylam Pharmaceuticals, Dicerna ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. During clinical trials, patients treated with Rivfloza ...
Over the past 20 years, we analyzed stones obtained from 74 patients with a diagnosis of primary hyperoxaluria type 1 established on the basis of complete urinary biochemical tests and evidence of an ...
Researchers gaining a better understanding of the genetic basis for oxalate absorption. Nephrolithiasis results from an interaction between diet and genetic predisposition. Most renal stones contain ...
An investigator-initiated trial examining YolTech Therapeutics’ in vivo gene editing-based ‘life-long cure’ for patients living with a rare genetic disorder has seen the treatment able to normalise ...
Built on next-generation CRISPR/Cas and LNP technologies, YolTech Therapeutics is pioneering in vivo gene-editing medicines with the potential for one-time, lifelong benefit. The company’s expanding ...
The autosomal recessive inherited primary hyperoxalurias types I, II and III are caused by defects in glyoxylate metabolism that lead to the endogenous overproduction of oxalate. Type III primary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results